Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220112 · ClinicalTrials.gov registry record · NA
Comparing Real-time fMRI Neurofeedback Versus Sham for Altering Limbic and Eating Disturbances in Anorexia Nervosa
A NA study of Anorexia Nervosa and Anorexia, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04220112: Completed NA study of Anorexia Nervosa and Anorexia, sponsored by University of Minnesota.
NCT04220112 is a NA study of Anorexia Nervosa and Anorexia that has completed, run by University of Minnesota. The registered enrollment target is 33 participants, below the 949-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04220112, a NA study of Anorexia Nervosa and Anorexia, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the purposed research is to extend prior work (STUDY00003758: Real-time fMRI Neurofeedback to Alter Limbic Disturbances in Anorexia Nervosa) on real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) as an innovative neurocircuitry-targeted intervention for anorexia nervosa (AN). This project will include randomization to rt-fMRI or a sham controlled group to answer the following important unresolved question: Does a patient-led procedure aimed at altering brain activity impact limbic circuit function and key eating disorder and psychiatric symptoms in AN above the effect of a matched, but non-targeted sham condition?
Primary Outcome
CHEDS is a 35-item self-report measure designed to assess eating disorder symptom changes over a short-term (i.e. weekly) time span. Items are presented using a Likert response format in which symptoms are rated from 0 (never) to 4 (always) during the past week. Total score is a sum of the 35 item scores.
Conditions Studied
Interventions
- PROCEDURE Sham Procedure
- PROCEDURE Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
What the finished NCT04220112 record still lists
NCT04220112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 949-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Anorexia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT04220112 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04220112 about?
NCT04220112 is a clinical study titled "Comparing Real-time fMRI Neurofeedback Versus Sham for Altering Limbic and Eating Disturbances in Anorexia Nervosa". The goal of the purposed research is to extend prior work (STUDY00003758: Real-time fMRI Neurofeedback to Alter Limbic Disturbances in Anorexia Nervosa) on real-time fMRI (rt-fMRI) neurofeedback (focused on amygdala down-regulation) as an innovative neurocircuitry-targeted intervention for anorexia ...
What is the current status of trial NCT04220112?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2020-03-01. Estimated completion is 2022-09-30.
What conditions does trial NCT04220112 study?
This clinical trial studies the following conditions: Anorexia Nervosa, Anorexia.
What interventions are being tested in trial NCT04220112?
The interventions under investigation include: Sham Procedure (PROCEDURE), Real-Time Functional Magnetic Resonance Imaging (RT-fMRI) (PROCEDURE).
Who is sponsoring clinical trial NCT04220112?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04220112 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04220112's enrollment target sits among peer trials
33 27th of 43 higher than 17 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Efficacy of Non-invasive Vagus Nerve Stimulation for Treatment of Low Weight Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI